Triggering of Protection Mechanism against Phoneutria nigriventer Spider Venom in the Brain

Catarina Rapoôso1, Paulo Alexandre Miranda Odoirissi1, Stefania Fioravanti Savioli1, Rafaela Chitarra Rodrigues Hell2, Gustavo Ferreira Simões2, Roberta R. Ruela-de-Sousa1, Alexandre Leite Rodrigues de Oliveira2, Maria Alice da Cruz-Höfling1*

1 Department of Biochemistry and Tissue Biology, State University of Campinas- Unicamp, Campinas, São Paulo, Brazil, 2 Department of Functional and Structural Biology, State University of Campinas- Unicamp, Campinas, São Paulo, Brazil

Abstract

Severe accidents caused by the “armed” spider Phoneutria nigriventer cause neurotoxic manifestations in victims. In experiments with rats, P. nigriventer venom (PNV) temporarily disrupts the properties of the BBB by affecting both the transcellular and the paracellular route. However, it is unclear how cells and/or proteins participate in the transient opening of the BBB. The present study demonstrates that PNV is a substrate for the multidrug resistance protein-1 (MRP1) in cultured astrocyte and endothelial cells (HUVEC) and increases mrp1 and cx43 and down-regulates glut1 mRNA transcripts in cultured astrocytes. The inhibition of NOS by 7-nitroindazole suggests that NO derived from nNOS mediates some of these effects by either accentuating or opposing the effects of PNV. In vivo, MRP1, GLUT1 and CX43 protein expression is increased differentially in the hippocampus and cerebellum, indicating region-related modulation of effects. PNV contains a plethora of Ca2+, K+ and Na+ channel-acting neurotoxins that interfere with glutamate handling. It is suggested that the findings of the present study are the result of a complex interaction of signaling pathways, one of which is the NO, which regulates BBB-associated proteins in response to PNV interference on ions physiology. The present study provides additional insight into PNV-induced BBB dysfunction and shows that a protective mechanism is activated against the venom. The data shows that PNV has qualities for potential use in drug permeability studies across the BBB.

Introduction

Accidents involving the “armed” spider Phoneutria nigriventer can cause neurotoxic manifestations, which in severe cases may include convulsion [1]. In experiments involving rats, P. nigriventer venom (PNV) impairs the BBB by increasing endothelial transcellular vesicular transport mediated by microtubules [2] and by down-regulation of inter-endothelial junctional proteins [3,4]. In astrocytes, PNV induces swelling of the perivascular end-feet [5], increases cytoskeletal GFAP and S-100 calcium metabolism-associated protein expression [6], and upregulates aquaporin-4 [7], a water channel-forming protein involved in edema formation and resolution. In neurons, PNV causes cFOS induction [3] and upregulation of VEGF and Flt-1 and Flk-1 receptors [8,9]. Increased understanding of the mechanisms involved in BBB dysfunction caused by PNV is beneficial from a medical perspective.

In the present study, MRP1 efflux pump activity was examined in cultured astrocytes and endothelial cells (HUVEC lineage) incubated with PNV. The effect of PNV on the mRNA transcripts of mrp1, glut1 and cx43 in astrocytes and the mediation of NO in the same was also analyzed. In vivo, the expression of these proteins was examined in the hippocampus and cerebellum of rats at different time-points following PNV exposure. The present study is of interest as investigations into the effect of animal venom on the BBB are rare. The use of PNV as a pharmacological tool to manipulate BBB can provide new insights on the changes that occur at the blood-brain interface. Spider venoms represent a rich mixture of proteins, peptides, neurotransmitters and small molecules with specific, highly potent effects on the nervous system of their prey or predators [10]. P. nigriventer venom contains Ca2+, K+ and Na+ channel-acting neurotoxins that affect neurotransmitter release and uptake [11]. Therefore its instrumental use for pharmacological characterization of proteins associated with the functioning of the BBB could be important for evaluating the possible therapeutic potential of PNV in neurochemical disturbances [10,12,13]. A positive factor is that severe envenomation by P. nigriventer occurs in less than 0.5% of accidents involving humans [1], and that in experimental cases the effects of PNV are resolved in a few hours. Thus it is important to further investigate the effect of PNV-induced BBB opening, taking
into consideration the pharmacological usefulness of the venom for drug permeability studies across the BBB. The study also contributes to a greater understanding of the envenomation profile of accidents involving *P. nigriventer*.

**Material and Methods**

**Animals**

*In vitro* assays used newborn Wistar rats (*Rattus norvegicus*, 0–2 days old) for harvesting astrocytes and *in vivo* assays used male Wistar rats (250–300 g), all obtained from an established colony maintained by the Multidisciplinary Center for Biological Investigation (CEMIB) at UNICAMP. Animals were kept in a 12/12 hour-light/dark cycle with food and water supplied *ad libitum*. The experiments were approved by the Institutional Committee for Ethics in Animal Use (CEUA, protocol no. 1429-1) and followed the Brazilian College for Animal Experimentation (COBEA) guidelines.

**Purified astrocyte primary cultures and HUVEC cells**

A primary culture of cerebral cortical-derived astrocytes was purified from 0–2 day-old newborn Wistar rats as previously described [4,14]. Human umbilical endothelial cell lines (HUVEC, ATCC #CRL-1730, Manassas, VA, USA) were cultured in DMEM containing 10% fetal bovine serum (FBS), supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and propagated at 37°C in a 5% CO2 humified atmosphere. Cells were seeded onto 24-well culture plates (10^4 cells/well).

**In vitro MRP1 efflux activity after treatment with PNV or PNV plus nNOS blocker**

Measurement of MRP1 activity in astrocytes and HUVEC was performed using a fluorescein substrate. Astrocytes or HUVEC were placed in a 6-well plate and treated with DMEM (control), PNV (14.6 μg/ml), only 7Ni (1 mg/ml) or PNV plus 7Ni (1 mg/ml) for 5 h. In the last two hours of treatment, a fluorescein substrate (100 μM) was added to the cells (uptake phase). The cells were then washed with PBS and incubated for 15 min in a completely fresh medium, without fluorescein, to allow fluorescein efflux by MRP1 (efflux phase). To evaluate the effect of PNV, PNV plus 7Ni, and 7Ni directly on MRP1 activity, these were added only during the efflux phase, for 15 min. Fluorescence was assessed by flow cytometry analysis within the live-gate, using FACScalibur (Becton and Dickinson - BD, Franklin Lakes, NJ, USA). Data was analyzed using Cell Quest Pro software (Becton and Dickinson – BD). The values correspond to the maximum fluorescence resulting from fluorescein uptake and are expressed in Relative Fluorescence Units (RFU). The values were obtained through three sets of experiments.

**In vitro mrp1, glut1 and cx43 mRNAs expression in astrocytes treated with PNV or PNV plus nNOS blocker**

Cultured astrocytes were treated with 1) DMEM (control); 2) 14.6 μg/ml of PNV freshly-diluted in DMEM [2]; 3) 7Ni
PNV plus selective nNOS blocker, 7-nitroindazole (7NI, 1 mg/ml) [15] for 2 h at 37°C. The mRNAs of the three proteins were measured. Then, astrocytes (~1x10^6 cells) were trypsinized, washed and the total RNA was extracted using a commercial extraction kit in accordance with the manufacturer’s instructions (Absolutely RNA Miniprep-GE). The concentration of isolated RNA samples was assessed by molecular absorption spectroscopy in the UV region, at 260 nm, and purity was assessed by calculating the ratio between absorbance at 260/280 nm. The reverse transcription from each sample (1 μg of total RNA) was performed with AffinityScript QPCR cDNA Synthesis Kit (Agilent Technologies, Santa Clara, CA, USA) in accordance with manufacturer’s instructions. Reverse transcription was carried out at 25°C for 5 min, and the products were then extended at 42°C for 30 min to allow cDNA synthesis. Finally, the reaction was terminated by heating at 95°C for 5 min. Samples without reverse transcriptase were processed in parallel and served as negative controls. The effect of PNV on the expression of several genes encoding MRP1, GLUT1 and Cx43 proteins was investigated by qRT-PCR using the Brilliant II SYBR Green QPCR Master Mix on Mx3005P QPCR Systems (Agilent Technologies).

Thermal cycling conditions were as follows: 10 min at 95°C followed by 40 amplification cycles at 95°C for 30 s, 55°C for one min and 72°C for one min. Depending on the type of primer, each reaction was performed using 1.0, 0.5 or 0.25 μM of forward and reverse primer and 100 ng of cDNA template in a final reaction volume of 25 μl. Melting curve analysis was performed at the end of the PCR to verify the identity of the products. The denaturation temperature was determined at the end of the amplification program, in a dissociation protocol that consisted of gradual 60°C to 95°C temperature increase at 0.5°C steps. The initiators were delineated based on the mRNA sequence described in Table 1. Additionally, whenever possible, PCR primers were designed to span adjacent exons in order to prevent amplification of the intron-containing genomic DNA. An efficiency curve was carried out for each primer using the serial dilution method. All quantifications were normalized to the housekeeping gene GAPDH and evaluated based on the control group from the Ct of these groups for each tested gene. A non-template control with non-genetic material was included to eliminate contamination or nonspecific reactions. Each sample was tested in duplicate and then used for the analysis of the relative transcription data using 2^(-ΔΔCT) method. Graphs showed relative gene expression, considering control as 1 (dotted line in graphs). Data is mean ± S.D.M. (***p<0.01 and ****p<0.001 vs. Control; ####p<0.001 vs. PNV; #####p<0.001 vs. 7NI/PNV).

doi:10.1371/journal.pone.0107292.g002

Figure 2. Effect of PNV and involvement of neuronal nitric oxide synthase in expression of mpr1, glut1 and cx43 genes, in astrocyte primary culture, by Real Time PCR. PNV increased mRNA levels of mpr1 and nNOS blockade by 7NI counteracted this effect. glut1 mRNA was decreased by PNV, but 7NI+PNV treatment also neutralized this PNV effect. However, cx43 mRNA level was increased by PNV and even more by 7NI plus PNV. In 7NI per se treated-astrocytes mpr1 gene expression was significantly above the level found in cell treated with 7NI/PNV; in contrast, glut1 and cx43 gene expression of astrocytes treated with 7NI alone was significantly below the level found in 7NI/PNV-treated cells. Fold change in genes expression was analyzed by the 2^(-ΔΔCT) method. Graphs showed relative gene expression, considering control as 1 (dotted line in graphs). Data is mean ± S.D.M. (***p<0.01 and ****p<0.001 vs. Control; ####p<0.001 vs. PNV; #####p<0.001 vs. 7NI/PNV).
Protection against *Phoneutria nigriventer* Spider Venom in the Brain

|          | HIP Cont | 15'-45' | 2 h | 5 h |
|----------|----------|---------|-----|-----|
| MRPI     |          |         |     |     |
| β-actin  |          |         |     |     |
|          | 170 KDa  |         |     |     |
|          | 42 KDa   |         |     |     |

|          | HIP Cont | 15'-45' | 2 h | 5 h |
|----------|----------|---------|-----|-----|
| GLUT1    |          |         |     |     |
| β-actin  |          |         |     |     |
|          | 50-52 KDa|         |     |     |
|          | 42 KDa   |         |     |     |

|          | HIP Cont | 15'-45' | 2 h | 5 h |
|----------|----------|---------|-----|-----|
| Cx43     |          |         |     |     |
| β-actin  |          |         |     |     |
|          | 42-44 KDa|         |     |     |
|          | 42 KDa   |         |     |     |
the 2−ΔΔCT method [16], taking into account the efficiency of each primer [17].

In vivo assays: Western blotting and immunofluorescence of MRP1, GLUT1 and Cx43

The animals (230–300 g) were divided into two groups. One group received a single intravenous (i.v.) injection of PNV (350 μg/kg in 0.5 ml) [5] in the tail vein, while the control (sham) group received the same volume of 0.9% sterile saline solution. At 30±15 min, 2 h and 5 h post-injection (n=5/time interval) the animals were killed with a 3:1 i.p. overdose of ketamine chloride (Dopalen; 100 mg/kg) and xylazine chloride (Anasedan; 10 mg/kg) anesthetics (Vetbrands, Jacarei, SP, Brazil). This time-window refers to the period of acute intoxication of the rats and their ongoing clinical recovery from a toxic condition [18].

Western Blotting (WB). Deeply-anesthetized (CO2 inhalation) animals were euthanized by decapitation. Cerebella and hippocampi were quickly dissected and homogenized in lysis buffer (10 mM EDTA, 2 mM PMSF, 100 mM NaF, 10 mM sodium pyrophosphate, 10 mM NaVO4, 10 mg of aprotinin/ml and 100 mM Tris, pH 7.4). Because control animals were alive and did not show signs of clinical impairment, their hippocampi and cerebella (from 30±15 min, 2 h or 5 h time-points) were mixed and homogenized to form a control pool (n=15). The expression of proteins of the control pool was compared with the PNV-30 ±15 min, PNV-2 h or PNV-5 h (n=5 per time) group. Homogenates were processed and underwent immunoblotting as described [6]. Briefly: after centrifugation (3000 g/10 min), the supernatant was collected and stored at −70°C. The proteins (50 μg) were separated on sodium dodecyl sulfate-polyacrylamide and electrophoretically transferred onto the nitrocellulose membrane (BioRad Laboratories, ref. 162-0115). After overnight blocking (5% non-fat milk) the membranes were incubated at room temperature for 4 h with primary antibodies described in Immunofluorescence sub-section (MRP1 – 1:200; GLUT1 – 1:400; Cx43 – 1:600 dilutions), followed by secondary horseradish peroxidase-antibodies (1:1000, Sigma). The blots were revealed using a chemiluminescence reagent (Super Signal, Pierce) and X-ray film (Fuji Medical, Kodak, Ref Z358487-50EA). Each band was quantified by densitometry using the IMAGEJ software (version 1.33u, NIH, USA). For each protein studied the results were confirmed in three sets of experiments. The blots were then stripped and reprobed for anti-β-actin analysis (1:250, Sigma) as a loading control for the other protein blots. Negative control was provided by omitting the primary antibody.

Immunofluorescence (IF). Rats were deeply anesthetized and then sequentially perfused transcardially with 150 μl of physiologic solution followed by fixative (250 μl of ice-cold 0.1 M phosphate-buffered saline (PBS) containing 4% paraformaldehyde, pH 7.4). The brains were dissected, frozen in liquid N2 and cryoprotected with 13% and 30% sucrose solution (24 hours each). Cryosections (12 μm thick) were mounted on silane-coated glass slides, air dried and then permeabilized with 0.1% Triton X-100 for 10 min at room temperature (RT) (only for GLUT1, before Triton X-100, the slices were incubated with ethanol, followed by methanol, for 10 min each, at −20°C), followed by 0.1% Tween 20 in TBS containing 5% non-fat milk at RT for 1 h. Subsequently, sections were reacted with anti-MRP1 (Zymed, 187246 - 1:100), anti-GLUT1 (Alpha Diagnostic, GT11-S - 1:100), anti-Cx43 (Sigma, C6219 – 1:500) and GFAP (Dako Cytomation, CA, USA, ZO 334 – 1:100) at 4°C (for GLUT1 only the incubation lasted 2 h in RT), and with FITC- or TRITC-conjugated monoclonal secondary antibody (Anti-rabbit IgG TRITC conjugate – T5268 – 1:1500; Anti-mouse IgG FITC conjugate – F6257 – 1:1500, Sigma) at RT for 1 h in the dark. Six images/animal (=30 images/time) were captured at random using a fluorescence BX51TF microscope (Olympus Optical C. Ltd., Tokyo, Japan) equipped with Image-Pro Plus 6.0 image analyzer software (Media Cybernetics Inc., USA). Quantification of the protein expression was performed with enhanced contrast and the density slicing feature of IMAGEJ software (version 1.33u, NIH, USA), which measures the intensity of immunofluorescence. Four sections per animal at each of the time-points (n=5 animals per time =20 sections/time) for the control and envenomed groups, were immunolabeled. The integrated density of pixels was measured by the total area (0.35 mm2) of captured images by C.R. and P.A.M.O. (double blinded measure).

Statistical analysis

The results were expressed as mean ± S.E.M. or mean ± S.D.M. All the numerical data were analyzed using the GraphPad Prism software package. One-way analysis of variance (ANOVA) followed by the Tukey-Kramer post-test was used to compare data from the control and PNV-treated samples. Statistical significance was set at p<0.05. Unpaired t-Student was used to compare each treatment with control.

Results

In vitro experiments: MRP1 activity

PNV-treated astrocytes. Fluorescence intensity was decreased significantly at 15 min comparing with DMEM-treated cells (control), suggesting efflux activity. At 5 h, the fluorescein efflux remained significant relative to control, but removal had decreased relative to PNV-15 min, indicating time-dependent MRP1 efflux activity (Figure 1A).

7NI/PNV-treated astrocytes. The fluorescence intensity was decreased significantly at 15 min relative to control (DMEM-treated) indicating fluorescein removal, whereas there was no difference relative to fluorescein removal at 5 h, thus indicating that the effect of nNOS-derived NO on the MRP1-efflux activity is time-dependent in isolated astrocytes (Figure 1A).

PNV-treated HUVEC. Fluorescence was significantly lower at 15 min after PNV exposure compared to control cells, but at 5 h the removal of fluorescein had diminished, thus indicating no significant difference between DMEM-treated HUVEC. This suggests that PNV treatment affects MRP1 activity time-dependently (Figure 1B).

7NI/PNV-treated HUVEC. Relative to the DMEM control, MRP1 efflux activity decreased significantly at 15 min post-treatment; the decrease was greater than in cells treated with PNV alone, thus indicating that the removal of fluorescein was potentiated in the absence of nNOS-derived NO. Interestingly, cells where removal activity had stopped after 5 h of treatment with PNV alone, when treated with 7NI+PNV for 5 h resulted in a significant decrease of fluorescence intensity, indicating reactiva-
Protection against *Phoneutria nigriventer* Spider Venom in the Brain

**MRP1 - Hippocampus**

A. Control - 5 h

B. PNV 15'-45'

C. PNV - 2 h

D. PNV - 5 h

**MRP1 - Cerebellum**

F. Control - 2 h

G. PNV 15'-45'

H. PNV - 2 h

I. PNV - 5 h

**Graphs**

F. Integrated density of pixels

- Control
- 15'-45'
- 2 h
- 5 h

J. Integrated density of pixels

- Control
- 15'-45'
- 2 h
- 5 h

* indicates significant difference.
tion of MRP1 activity (Figure 1B). The findings seem to indicate that NO signaling re-activates efflux exhaustion of MRP1. 

**7NI-treated astrocytes and HUVEC.** 7NI alone, used as control, did not show significant differences in the MRP1 efflux activity when compared with that of 7NI/PNV, in two tested periods (15 min and 5 h), in both astrocytes and HUVEC cells.

**In vitro experiments: Quantitative Real Time-PCR (qRT-PCR) analysis**

**mrp1.** PNV-treated astrocytes showed a 38% increase of mrp1 mRNA level at 2 h. Treatment with 7NI plus PNV significantly counteracted the effects of PNV leading to a 67% reduction below the level found in PNV-treated cells and a 29% reduction relative to baseline (Figure 2A). In the 7NI-treated astrocytes mrp1 gene expression was significantly above the level found in cells treated with 7NI/PNV, but significantly below that found in PNV-treated cells.

**glut1.** PNV decreased glut1 mRNA by 20% below baseline in cultured astrocytes. The inhibition of nNOS (7NI/PNV-treated astrocytes) reversed this effect by promoting a 12% increase above baseline and a 32% increase compared to PNV-treated cells (Figure 2B). 7NI per se decreased glut1 gene expression in relation to 7NI/PNV treatment; however, the decrease was minor than the found in PNV-treated cells.

**cx43.** Two hours of PNV exposure induced a 25% increase in cx43 mRNA in astrocytes, compared to the physiological level of untreated cells. Co-exposure of 7NI + PNV elevated the mRNA expression to 56% above baseline and 26% above the level found in PNV-treated astrocytes (Figure 2C). Incubation with 7NI alone significantly decreased gene expression compared with 7NI/PNV treated cells.

**In vivo experiments: WB data**

**MRP1.** While hippocampal MRP1 level increased by 70% in PNV-treated rats at 5 h, in the cerebellum the protein level remained unchanged at all post-envenoming time-points (Figure 1A, B, C).

**GLUT1.** At 5 h following treatment of rats with PNV increases of 81% and 32% were observed in the hippocampal and cerebellar GLUT1, respectively, relative to saline-treated rats (Figure 3D, E, F).

**Cx43.** The total level of the main gap junction-forming protein remained unchanged in the hippocampus and cerebellum throughout the time-points post-PNV envenoming (Figure 3G, H, I).

**In vivo experiments: IF data**

**MRP1.** MRP1 immunolabeling appeared as fluorescent dots outlining the endothelial wall of the hippocampal and cerebellar microvessels. At 5 h, PNV-treated animals showed a 62% increase in the MRP1 expression in hippocampus and a 66% increase at 2 h in the cerebellum in relation to respective control group (Figure 4A–J).

**GLUT1.** Anti-GLUT1 immunolabeling was tenuous and discontinuous around vessels in controls; PNV promoted 80% (2 h) and 102% (5 h) significant increases in anti-GLUT1 reactivity around vessels and across the parenchyma, mainly in the hippocampus (see *v*). In the cerebellum of PNV-treated rats, anti-GLUT1 was increased at 5 h, compared to control (Figure 5A–J).

**Cx43.** In the control group, Cx43 immunoreactivity outlined microvessels in the hippocampus and cerebellum. This was faint in the Purkinje and granular layers (Figure 6A and 6F). PNV treatment induced an immediate enhancement of labeling in both layers followed by a gradual decrease (Figure 6B–D and 6G–I). Comparing with the control group, the quantification of pixel density (Figure 6E) showed a 56% increase in the hippocampus and a 64% increase in the cerebellum in anti-Cx43 staining, followed by a 200% decrease below baseline (5 h) in the hippocampus only.

**Cx43 and GFAP.** In order to show that increases of Cx43 level paralleled with increases of GFAP in PNV-treated rats, frozen sections of the cerebellum (Figure 7) and hippocampus (not shown) were immunostained for GFAP and Cx43. Compared to controls (panels A, B, C, D), animals exposed to PNV showed an immediate (at 15–45 min) increase in the expression of Cx43 (see also IF and WB data) and induced GFAP expression in reactive astrocytes (panels E, F, G, H). Co-localization of Cx43 and GFAP was intense around Purkinje cells, granule neurons, the wall of vessels, and in astrocytic processes within the molecular layer. As expected, while Cx43 labeling appeared as serial dots, GFAP labeling was continuous, since gap junctions form isolated communicating channels in the plasma membrane, while GFAP is part of the intermediate filaments of the glial cytoskeleton distributed along the astrocyte processes and perikaryum. In the hippocampus, GFAP and Cx43 labeling increased around blood vessels and throughout the hippocampal parenchyma (not shown).

**Discussion**

The results of the present study found that *P. nigriventer* armed-spider venom is a substrate for MRP1 activity in endothelial and astrocyte cells. PNV also affected the expression of mrp1, glut1 and cx43 mRNAs transcripts in astrocytes. Furthermore, evidence suggests that NO derived from nNOS could synergistically and/or antagonistically mediate the PNV effects. *In vivo*, the venom alters the translational expression of MRP1, GLUT1 and Cx43 proteins in the microvessel wall. Cx43 upregulation was detected in reactive astrocytes of the cerebellum and hippocampus and outlining the Purkinje neurons. All of these effects were time- and cell/region-modulated. To the best of the authors’ knowledge this is the first study to show alterations of these proteins by spider venom that disrupt the BBB, and that is also known to affect other neurovascular systems [13].

The present immunohistochemistry-based *in vivo* MRP1 labeling is in conformity with its strategic location at the ECs of brain microvessels [18] and end-feet processes of astrocytes [19,20]. *In vitro*, the ready increase in MRP1 activity in ECs and astrocytes as early as 15 min after venom exposure coincides with the onset of signs of serious intoxication of the animals. The increase in MRP1 efflux activity suggests a rapid induction of a pro-homeostasis protective mechanism. However, 51h later, endothelial cells no longer showed efflux activity while astrocytes showed activity deceleration in comparison with that seen at 15 min. Clinically, at this time-point the animals showed signs indicating that recovery of intoxication is underway [6,21]. The
absence of MRP1 activity in ECs and its slowdown in astrocytes at 5 h may imply that an appreciable amount of venom has been pumped out or that the efflux mechanism has undergone interference of second messengers, or both.

One such candidate is nitric oxide, a second messenger already known to affect transport at the blood-brain interface [22–24]. MRP1 belongs to the ATP-driven efflux pump family of transmembrane multidrug resistance-associated proteins (MDR) which mediate the removal of cytotoxic substances and drugs from the CNS. MRP1 acts as a glutathione S-conjugate efflux pump (GS-X pump) by transporting organic anions and several drugs which are conjugated with glutathione (GSH) [25]. The present findings found that nNOS-derived NO could be one of the mediators of the PNV effect at the BBB, and that the mediation is modulated according to the type of cells and time of venom exposure. The involvement of the nNOS/NO system has been already described to mediate the cavernosal relaxation induced by PnTx2-6, a toxin isolated from PNV [13,26]. Therein, the toxin neurovascular effect was potentiated by NO produced by nNOS.

In the present study, the co-treatment of ECs with PNV plus the selective nNOS inhibitor (7NI) not only promoted enhancement of efflux activity at 15 min but reactivated pump activity at 5 h. The improvement of pump activity in the absence of nNOS-derived NO suggests that at that time-point (5 h) the NO dampens efflux activity, so working antagonistically to the efficiency of toxicant removal in ECs. Conversely, on the glial cells, the effect of NO seems to contribute positively to the removal of the toxicant, since MRP1 efflux activity in astrocytes treated with 7NI + PNV, which was in process in cells incubated with PNV alone, stopped efflux activity in the absence of NO produced by nNOS. Such effect was time-dependent, as it was only found at 5 h. At 15 min, efflux activity was maintained in 7NI/PNV-treated astrocytes equal to that found in PNV-treated cells. The findings suggest that NO intervention in MRP1 activity can be temporally diverse and can depend on cell-type. The results also show that astrocytes possess a more efficient mechanism for substrate (PNV) extrusion than the peripheral ECs used herein. Available literature indicates that the amount of MRP1 is greater in astrocytes than in the brain ECs of rats [27,28] leading to the conclusion that astrocytes possess an efficient mechanism against drug (PNV) accumulation.

Besides NO, other mechanisms could affect the temporally-related MRP1 activity changes. The possibility that the pump could be rendered defective by the toxic accumulation of PNV inside the astrocytes or by failure in the conjugation of GSH, or another reason, cannot be discarded. In fact, relevant evidence shows that the transporter activity of MRP1 can be caused by endogenous-induced alterations in the glutathione metabolism [29–31]. Relevant literature reports links between MRP1 drug resistances vs. GSH cellular levels vs. drug-metabolizing cytochrome P450 (CYP) induction in response to xenobiotics. CYP enzymes encompass a super-family of hemoproteins that play a role in the biotransformation of a wide range of endogenous and exogenous compounds [32]. CYP induction in response to xenobiotics occurs concomitantly with the generation of free radicals and depletion of intracellular GSH content [29,30]. This hinders MRP1 activity as it requires conjugation or co-transportation of drugs and organic ions with GSH. The presence of the drug-metabolizing cytochrome P450 in cultured endothelial cells and primary astrocytes [29,33] and in the wall of blood vessels, astrocytes of the cerebellum and pyramidal neurons of all hippocampal subfields [34,35] evidences the existence of endogenous alterations in GSH levels, and hence in MRP1 activity.

The inhibition of MRP1 activity has been also reported to occur through changes in the conformation of the MRP1 molecule [25,36]. However, this did not seem to be the case in the present study, the data of which indicates that mrp1 gene activity remained active, since mrp1 mRNA increased in cultured astrocytes treated with PNV (Figure 2). In agreement, the translational event was not affected, since PNV-treated rats showed increased expression of MRP1 in the hippocampus and cerebellum (Figure 3 and 4). Altogether, the data cast doubt on the capacity of MRP1 to make conjugates and export them from PNV-treated cells. Further studies are necessary to clarify this, and to verify GSH stores inside the cells.

In relation to mediation by NO, it was noted that at the transcription level NO acted proactively in relation to MRP1 transcription, since in the absence of NO-derived nNOS (7NI+ PNV-treated astrocytes) mRNA expression decreased significantly relative to both control and PNV-treated astrocytes. The data suggests that the gas acts synergistically with PNV promoting the increase of mrp1 mRNA transcripts. This is worthy of note because in relation to MRP1 activity, NO inhibits the extrusion activity of the protein.

The complexity of NO mediation was also seen in relation to the influx transporter, GLUT1. 7NI+PNV treatment increased glut1 gene expression which had been reduced by PNV alone. The finding reveals that NO produced by nNOS may have had a critical role in a possible reduction of the facilitative glucose transporter promoted by the spider venom and hence in a supposed lower supply of energy fuel from astrocytes for brain metabolism [37]. Nevertheless, the hippocampus and cerebellum of rats treated with PNV showed increased expression of GLUT1 indicating that translational events were stimulated by the venom. Such apparent discrepancy may be attributed to in vivo versus in vitro experiments and different time scales, but also to sometimes divergent regulatory mechanisms acting at the translational stage and respective coding gene [38].

Little has been reported about interaction between multidrug resistance protein and glucose transporter protein. However, it is conceivable that cytotoxic insult to the CNS would demand greater resources of glucose and a mechanism for eliminating the toxic agent. In fact, studies in vitro cell lines have shown an increased rate of facilitative glucose transport and level of GLUT1 expression in parallel with increased vincristine resistance, active vincristine efflux and decreased vincristine steady-state accumulation. Moreover, glucose transport inhibitors (cytochalasin B and phloretin) block the active influx and increase steady-state accumulation of vincristine [39]. Contrastingly, increased expression/content of GLUT1 reflects elevated levels of circulating glucose, and the increase of brain glucose utilization has been correlated positively with elevated expression of GLUT1 and vice-versa [40]. It may be suggested that significant increases of GLUT1 in the hippocampus and cerebellum of PNV-treated rats could be evidence of enhanced glucose transport and probable high energy metabolism demand after envenomation. The significant increase of glut1 transcripts after the inhibition of

**Figure 5. Immunofluorescence (IF) for GLUT1 in hippocampus (A–D), and cerebellum (F–I).** In hippocampus, GLUT1 immunolabeling increased 2 and 5 hours after envenoming. In the cerebellum, no significant changes were observed. E and J show the IF densitometric values for the hippocampus and cerebellum, respectively (∗p<0.05, **p<0.01 relative to control). Values represent the mean ± S.E.M. The results were confirmed in three sets of experiments. v = blood vessel, * = labeled parenchyma. N = 5 per group. Bar = 35 μm.
Figure 6. Immunofluorescence (IF) for Cx43 in hippocampus (A–D) and cerebellum (F–I). Cx43 expression was increased after 15–45' in the hippocampus and cerebellum. In the hippocampus, there was an intense decrease after 5 h of envenoming. E and J show the IF densitometric values for hippocampus and cerebellum, respectively (*p<0.05, **p<0.01 compared to control). Values represent the mean ± S.E.M. The results were confirmed in three sets of experiments. v = blood vessel; * = labeled parenchyma; GL – glomerular layer; ML – molecular layer; PCL = Purkinje cell layer. Bars = 70 μm (A–D, F, G, I); 35 μm (H).
doi:10.1371/journal.pone.0107292.g006
nNOS revealed that NO mediation is synergic with PNV against facilitative glucose transport. The results of the present study indicate that PNV is a useful tool for research into MDR phenotype development, drug efflux and glucose uptake mechanisms.

PNV increased *cx43* gene expression, an effect that was potentiated by the absence of NO produced by nNOS. The increases in the *cx43* transcripts suggest increased preparation for translational events, with NO antagonistically mediating the effects of PNV. The increase in *cx43* gene activity *in vitro* paralleled increases in Cx43 protein expression, though the latter was only observed through the density of pixels of anti-Cx43 labeling (IF data) but not in the total amount of protein in the hippocampus and cerebellum (WB data). The lack of significance obtained from WB analysis indicates that the formation of new intercellular channels is not uniform throughout the cerebellum and hippocampus parenchyma as previously reported [41]. In fact, the increase of Cx43 immunoreactivity was marked around blood vessels and around Purkinje and granule neurons but less expressive in the molecular layer of the cerebellum (Figure 7).

**Figure 7. Cx43 and GFAP immunofluorescence in sections of cerebellum.** A–D showed control group and E–H showed PNV-15-45 group. There is a correlation between Cx43 and GFAP labeling (arrows and arrowheads). This indicated that Cx43 are positive mainly in astrocytes. G = Granular layer, P = Purkinje layer, M = Molecular layer, v = blood vessel. Bar = 70 μm for all panels.
doi:10.1371/journal.pone.0107292.g007
Such increases in Cx43 expression occurred 15 to 45 min after envenomation when animals already manifested signs of intense intoxication [4,9,21]. At subsequent time-points, Cx43 staining underwent a major reduction in the hippocampus and showed a tendency for reduction in the cerebellum (Figure 6), coincidently with amelioration of the toxic condition of the animals [4,8,21]. The increase of Cx43 protein expression implies the establishment of intercellular channels for diffusion of chemical and electrical information between the reactive (GFAP+) astrocytes [42]. Connexin 43-formed channels are strictly linked to modifications of ionic composition of extracellular CNS compartment, with calcium oscillations possessing a critical role [43]. PNV contains excitotoxic neuropeptides [11] and PnTx1-3, a neurotoxin isolated from PNV, has been shown to increase the frequency of Ca2+ oscillations in in vitro GH3 cells [44]. The significant further reduction of Cx43 expression, especially in the hippocampus (5 h post-PNV), could be a mechanism for avoiding cell damage [45], since PNV induces FOS induction (2 h post-PNV) in neurons [6] and the decrease of gap junctions (GJs) formation/communication in astrocytes could be controlled by neurons [42].

A further interesting point is the relationship between Cx43 and glucose metabolism. Molecular pathways suggest a potential link between GJs and energy metabolism in astrocytes. Studies have shown that the inhibition of Cx43 increases glucose transport by astrocytes through GJs [46] and up-regulation of GLUT1 [47], which is then associated with up-regulation of Na+/K+-ATPase activity [48]. The basis of this relationship is still unknown, but could be related to the blocking effect of PNV on K+ channels [11]. The data indicates that PNV is instrumental for studies related to the interaction of Cx43, GLUT1 and MRPI.

In conclusion, the present study shows that the PNV is a substrate for MRPI activity. Also, the study provides evidence that nNOS-derived NO is involved in the mediation of PNV effects, apparently through a complex dual mediation at the BBB level: as an enhancer of mrp1 transcription in astrocytes and as an inhibitor of MRPI efflux activity in endothelial cells. Data showing differences between the type of cells and between the hippocampus and cerebellum, two regions in which PNV disrupts the BBB, is interesting as it allows the detection of regional differences in energy metabolism, capacity for drug exclusion/distribution and communication between cells in PNV-intoxicated rats. The study not only provides information for therapeutic purposes in relation to victims of *Phoneutria nigriventer* envenomation, but also reveals the potential natural resources that exist in venomous fauna (particularly rich in Brazil) in terms of pharmacologically active components.

**Acknowledgments**

The authors thank Instituto Butantan (São Paulo, SP, BR) for venom donation, Prof. Cristina Vicente (DBEF, IB/Unicamp) for kindly providing HUVEC cells, Mrs. Marta R. Leonardo (BSv) for excellent technical assistance and Mr. Miguel Silva and Mr. Marcos Silva for animal care. The authors acknowledge the English editing by Mr. James Young.

**Author Contributions**

Conceived and designed the experiments: MACH CR. Performed the experiments: CR PAMO SGS RCR RRRS. Analyzed the data: MACH CR PAMO. Contributed reagents/materials/analysis tools: MACH ALRO RRRS. Contributed to the writing of the manuscript: MACH CR.

**References**

1. Bucaretchi F, De Souza CR, Hyslop S, Madureira PR, De Capitani EM, et al. (2000) A clinic-epidemiological study of bites by spiders of the genus *Phoneutria*. Rev Inst Med Trop Sao Paulo 42: 17–21.
2. Le Sueur LP, Collares-Buzato CB, Cruz-Hofling MA (2004) Mechanisms involved in the blood-brain barrier increased permeability induced by *Phoneutria nigriventer* spider venom in rats. Brain Res 1027: 36–47.
3. Cruz-Hofling MA, Zago GM, Melo LL, Raposo C (2007) c-FOS and n-NOS reactive neurons in response to circulating *Phoneutria nigriventer* spider venom. Brain Res Bull 73: 114–126.
4. Raposo C, Odorni PAM, Oliveira ALR, Aoyama H, Ferreira CV, et al. (2012) Effect of *Phoneutria nigriventer* niger venom on the expression of junctional protein and P-gp efflux pump function in the blood-brain barrier. Neurochem Res 37: 1897–1901.
5. Le Sueur LP, Kalapothakis E, Cruz-Hofling MA (2003) Breakdown of the blood-brain barrier and neuropathological changes induced by *Phoneutria nigriventer* spider venom. Acta Neuropathol 105: 125–134.
6. Cruz-Hofling MA, Raposo C, Verenaud L, Zago GM (2009) Neuroinflammation and astrocytic reaction in the course of *Phoneutria nigriventer* (armed spider)-blood-brain barrier (BBB) opening. NeuroToxicology 30: 636–646.
7. Stável LM, Soares ES, Mendonça MC, Irazusta SP, Cruz-Hofling MA (2006) Temporal relationship between aquaporin-4 and glial fibillary acidic protein in cerebellum of neonate and adult rats administered a BBB disrupting spider venom. Toxicol Sexon: 37–46.
8. Mendonça MCF, Soares ES, Stável LM, Irazusta SP, da Cruz-Hofling MA (2012) Upregulation of the vascular endothelial growth factor, Flt-1, in rat hippocampal neurons after envenoming by *Phoneutria nigriventer*, age-related modulation. Toxicology 60: 656–664.
9. Mendonça MCF, Soares ES, Stável LM, Raposo C, Coope A, et al. (2013) Expression of VEGF and Flk-1 and Flt-1 receptors during blood-brain barrier (BBB) impairment following *Phoneutria nigriventer* spider venom exposure. Toxins (Basel) 5: 2572–2588.
10. Bosmans F, Escobas P, Nicholos GM (2009) Spider venom peptides as leads for drug and insecticide design. In: Lima ME. Pimenta AMC, Lima ME (2009) Animal toxins as potential tools for treatment of erectile dysfunction. In: Lima ME. Pimenta AMC, Martin-Eauclaire, Zingali R, Rochat H, editors. Animal Toxins: State of the Art. Perspectives in Health and Biotechnology. Belo Horizonte: UFMG Editora. pp. 269–290.
11. Bucaretchi F, Deus Reinaldo CR, Hyslop S, Madureira PR, De Capitani EM, et al. (2000) A clinic-epidemiological study of bites by spiders of the genus *Phoneutria*. In: Lima ME. Pimenta AMC, Martin-Eauclaire, Zingali R, Rochat H, editors. Animal Toxins: State of the Art. Perspectives in Health and Biotechnology. Belo Horizonte: UFMG Editora. pp. 269–290.
12. Abbott NJ, Rønbaøck L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. In: Lima ME. Pimenta AMC, Martin-Eauclaire, Zingali R, Rochat H, editors. Animal Toxins: State of the Art. Perspectives in Health and Biotechnology. Belo Horizonte: UFMG Editora. pp. 313–322.
13. Le Sueur LP, Collares-Buzato CB, Cruz-Hofling MA (2004) Mechanisms involved in the blood-brain barrier increased permeability induced by *Phoneutria nigriventer* spider venom in rats. Brain Res 1027: 36–47.
14. Moore PK, Wallace P, Gaffen Z, Hart SL, Babbedge RC (1993) Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: antinociceptive and cardiovascular effects. Br J Pharmacol 110: 219–224.
15. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) method. Methods 25: 402–408.
16. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: 2002–2007.
17. Hsiai-Yun H, Seerst DT, Mark KS, Carney D, Brandquist C, et al. (1998) Expression of multidrug resistance-associated protein (MRP) in brain microvesel endothelial cells. Biochem Biophys Res Commun 256: 816–820.
18. Arosina E, Gomez JA, Ramkem A, Redeker S, Orbias-Gyenge F, et al. (2004) Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 45: 441–451.
19. Schober R, Dringen R (2011) Copper-treatment increases the cellular GSH content and accelerates GSH export from cultured rat astrocytes. Neurosci Lett 491: 42–46.
20. Raposo C, Zago GM, da Silva GH, da Cruz-Hofling MA (2007) Acute blood-brain barrier permeability in rats after systemic *Phoneutria nigriventer* venom. Brain Res 1149: 18–29.
21. Abbott NJ, Rønbaøck L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev 7: 41–53.
22. Rettingerov BI, Mertsch K, Sporbert A, Tenz K, Paul M, et al. (1998) Nitric oxide and inosenzymes regulate lipopoly saccharide-enhanced insulin transport across the blood-brain barrier. Endocrinology 139: 1514–1523.
23. Banks WA, Dohgu S, Lynch JL, Fleegal-DeMotta MA, Erickson MA, et al. (2005) Nitric oxide protects blood-brain barrier in vitro from hypoxia/reoxygenation-mediated injury. FERS Lett 424: 197–201.
24. Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, et al. (1994) Overexpression of the gene encoding the multidrug resistance-associated protein...
results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91: 13033–13037.

26. Nunes KP, Wynne BM, Cordeiro MN, Borges MH, Richardson M, et al. (2012) Increased cavernosal relaxation by Phoneutria nigriventer toxin, PnTx2-6, via activation at NO/cGMP signaling. Int J Impot Res 24: 69–76.

27. Declèves X, Regina A, Laplanche JL, Roux F, Boval B, et al. (2000) Functional expression of Pglycoprotein and multidrug resistance-associated protein (MRP1) in primary cultures of rat astrocytes. J Neurosci Res 60: 594–601.

28. Hayashi K, Pu H, Andras H, Eam SY, Yamauchi A, et al. (2006) HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab 26: 1052–1065.

29. Decle`ves X, Regina A, Laplanche JL, Roux F, Boval B, et al. (2000) Functional expression of P-glycoprotein and multidrug resistance-associated protein (MRP1) in primary cultures of rat astrocytes. J Neurosci Res 60: 594–601.

30. Hayashi K, Pu H, Andras H, Eam SY, Yamauchi A, et al. (2006) HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab 26: 1052–1065.

31. Chuman Y, Chen ZS, Seto K, Sumizawa T, Furukawa T, et al. (1998) Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. Cancer Lett 129: 69–76.

32. Ortiz de Montellano PR, Grab LA (1986) Cooxidation of styrene by horseradish peroxidase and glutathione. Mol Pharmacol 30: 666–669.

33. Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, et al. (2009) Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 77: 897–909.

34. Hansson T, Tindberg N, Ingelman-Sundberg M, Ko¨hler C (1990) Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system. Neuroscience 34: 451–463.

35. Hagemeyer CE, Rosenbrock H, Ditter M, Knoth R, Volk B (2003) Predominantly neuronal expression of cytochrome P450 isoforms CYP3A11 and CYP3A13 in mouse brain. Neuroscience 117: 521–529.

36. Versantvoort CH, Broxterman HJ, Bagari T, Schepers R, Tw Penneman PR (1995) Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 72: 82–89.

37. Virginino D, Robertson D, Monaghan P, Eredde M, Bertossi M, et al. (1997) Glucose transporter GLUT1 in human brain microvessels revealed by ultrastructural immunocytchemistry. J Submicrosc Cytol Pathol 29: 365–370.

38. Schwandhauser B, Busse D, Li N, Dittmar G, Schuchhardt J, et al. (2011) Global quantification of mammalian gene expression control. Nature 473: 337–342.

39. Martell RL, Slapak CA, Levy SB (1997) Effect of glucose transport inhibitors on vincristine efflux in multidrug-resistant murine erythroleukaemia cells overexpressing the multidrug resistance-associated protein (MRP) and two glucose transport proteins, GLUT1 and GLUT3. Br J Cancer 75: 161–168.

40. Choeiri C, Staines W, Miki Y, Seino T, Mønster C (2005) Glucose transporter plasticity during memory processing. Neuroscience 130: 591–600.

41. Karpik N, Burkovetskaya M, Fritz T, Ange A, Kirihan T (2011) Neuroinflammation leads to region-dependent alterations in astrocyte gap junction communication and hemichannel activity. J Neurosci 31: 414–423.

42. Rouach N, Koulakoff A, Giaume C (2004) Neurons set the tone of gap junctional communication in astrocytic networks. Neurochem Int 45: 263–272.

43. De Bock M, Wang N, Decrock E, Boel M, Gadicheria AK, et al. (2013) Endothelial calcium dynamics, connexin channels and blood-brain barrier function. Progress in Neurobiology 108: 1–20.

44. Kushmerick C, Kalapothakis E, Beirão PS, Penaforte CL, Prado VF, et al. (1999) Phoneutria nigriventer toxin Tx3-1 blocks A-type K⁺ currents controlling Ca²⁺ oscillation frequency in GH3 cells. J Neurochem 72: 1472–1481.

45. Gangoso E, Ezan P, Valle-Casuso JC, Herrero-Gonzalez S, Koulakoff A, et al. (2012) Reduced connexin43 expression correlates with c-Src activation, proliferation, and glucose uptake in reactive astrocytes after excitotoxic insult. Glia 60: 2040–2049.

46. Tabernero A, Medina JM, Giaume C (2006) Glucose metabolism and proliferation in glia: role of astrocyte gap junctions. J Neurochem 99: 1049–1061.

47. Herrero-Gonzalez S, Valle-Casuso JC, Sanchez-Alvarez R, Giaume C, Medina JM, et al. (2009) Connexin43 is involved in the effect of endothelin-1 on astrocyte proliferation and glucose uptake. Glia 57: 222–233.

48. Giaume C, Tabernero A, Medina JM (1997) Metabolic trafficking through astrocytic gap junctions. Glia 21: 114–123.